Catabasis Pharmaceuticls Company Profile (NASDAQ:CATB)

Analyst Ratings

Consensus Ratings for Catabasis Pharmaceuticls (NASDAQ:CATB) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.75 (506.67% upside)

Analysts' Ratings History for Catabasis Pharmaceuticls (NASDAQ:CATB)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016WedbushReiterated RatingOutperform$27.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016Citigroup Inc.Lower Price TargetBuy$21.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Catabasis Pharmaceuticls (NASDAQ:CATB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2016Q1($0.64)($0.61)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2016Q415($0.69)($0.63)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.64)($0.55)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catabasis Pharmaceuticls (NASDAQ:CATB)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.63)($0.60)($0.62)
Q2 20162($0.65)($0.61)($0.63)
Q3 20162($0.67)($0.61)($0.64)
Q4 20162($0.69)($0.61)($0.65)
Q1 20171($0.73)($0.73)($0.73)
Q2 20171($0.80)($0.80)($0.80)
Q3 20171($0.91)($0.91)($0.91)
Q4 20171($1.05)($1.05)($1.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catabasis Pharmaceuticls (NASDAQ:CATB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Catabasis Pharmaceuticls (NASDAQ:CATB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/30/2015Medimmune Ventures, Inc.Major ShareholderBuy223,439$12.00$2,681,268.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015Nicholas GalakatosDirectorBuy376,695$12.00$4,520,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Catabasis Pharmaceuticls (NASDAQ:CATB)
DateHeadline
07/29/16 04:44 AMCatabasis Pharmaceuticals to Report Second Quarter 2016 Financial Results and Recent Corporate Developments on ... - Business Wire (press release)
07/23/16 07:22 AMCatabasis Pharmaceuticals Inc Can't Be More Safe. Trades Significantly Higher - Press Telegraph
07/21/16 07:28 AMTracking Analyst Ratings and Target Projections for: Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Press Telegraph
07/21/16 07:28 AMStock Moving Lower for the Month; Investor Update on Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Engelwood Daily
07/21/16 07:28 AMCatabasis Pharmaceuticals Inc (NASDAQ:CATB): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 07:28 AMEarnings Focus and Crowd Sourced Sentiment Review for Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - TGP
07/18/16 03:14 PMTrading Performance and Target Watch for Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Press Telegraph
07/17/16 02:54 PMCatabasis Pharmaceuticals, Inc. (CATB) Broker Price Targets For The Coming Week - Fiscal Standard
07/14/16 03:09 PMCatabasis Pharmaceuticals, Inc. (CATB) Updated Price Targets - FTSE News
07/14/16 03:09 PMCatabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Short Interest Increased By 2.74% - Consumer Eagle
07/14/16 03:09 PMCrowd Rating and Earnings Recap for Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Telanagana Press
07/12/16 07:00 AMCatabasis Pharmaceuticals Names Joseph Johnston VP, Regulatory Affairs - [Business Wire] - Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it has named Joseph Johnston as Vice President, Regulatory Affairs. Mr.
07/11/16 09:01 AMAdvicent introduces Narrator® Clients powered by NaviPlan® in its latest release - [Business Wire] - Advicent is pleased to announce that their newest financial planning portal, Narrator Clients, will now be powered by NaviPlan, as part of the financial planning tool’s latest version update.
07/07/16 10:55 AMCatabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying ... - Yahoo Finance
07/07/16 07:21 AMCatabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the initiation of an open-label extension for ...
07/07/16 07:03 AM8:03 am Catabasis Pharmaceuticals announces initiation of open-label extension for the Phase 2 portion (Part B) of the MoveDMD trial studying edasalonexent in boys with Duchenne muscular dystrophy -
07/06/16 07:52 AMShares Dropping Lower in Session: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Telanagana Press
07/06/16 07:52 AMCatabasis Pharmaceuticals, Inc. (CATB) Current Analyst Ratings - Fiscal Standard
07/03/16 07:46 AMCompany Stock Lower on the Week Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Engelwood Daily
07/01/16 03:18 PMCATABASIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -
07/01/16 03:04 PMTime to Buy Catabasis Pharmaceuticals Inc After Today's Huge Decline? - Engelwood Daily
06/29/16 08:07 PMCatabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Sellers Increased By 2.74% Their Shorts - Engelwood Daily
06/28/16 07:34 PMShare Update and Earnings Review for Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Press Telegraph
06/28/16 02:24 PMToday's Watch List: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), Blue Capital Reinsurance Holdings Ltd. (NYSE ... - KC Register
06/28/16 02:24 PMCatabasis Pharmaceuticals Inc (NASDAQ:CATB) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 02:24 PMEquity Research and Technical Review on Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Press Telegraph
06/28/16 02:24 PMNext Weeks Broker Price Targets For Catabasis Pharmaceuticals, Inc. (CATB) - Fiscal Standard
06/20/16 03:02 PMCATABASIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 09:27 AMCatabasis Pharmaceuticals (NASDAQ:CATB) target price dropped to $8 as recorded today by Citigroup
06/20/16 07:00 AMCatabasis Pharmaceuticals to Present Edasalonexent (CAT-1004), an Oral Agent Targeting NF-kB: MoveDMDSM Trial in Duchenne Muscular Dystrophy (DMD) at the 2016 PPMD Annual Connect Conference - [Business Wire] - Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that edasalonexent will be featured in an oral presentation and a poster presentation at the upcoming 2016 Parent Project Muscular Dystrophy Annual Connect Conference being held on Sunday, June 26 – Wednesday, June 29, 2016 at the Renaissance Orlando at Sea World Hotel in Orlando, FL.
06/08/16 09:29 PMCatabasis Pharma (CATB) Announces CAT-2054 Phase 2a Missed Primary Endpoint in Hypercholesterolemia
06/08/16 09:29 PMDrug Data Deals a Blow to Catabasis Pharmaceuticals Inc (CATB)
06/08/16 05:05 PMCatabasis Pharmaceuticals, Inc. :CATB-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/08/16 11:09 AM5 Stocks That Are Getting Battered and Bruised Today -
06/08/16 07:28 AMCatabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on MoveDMDSM: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar ...
06/07/16 08:41 PMCatabasis shares halted as cholesterol drug misses study goal
06/07/16 04:19 PMCatabasis shares fall 50% as cholesterol drug misses study goal -
06/07/16 03:53 PMCatabasis Pharma's cholesterol drug fails mid-stage study -
06/07/16 03:48 PMCatabasis Pharmaceuticals Announces Top-Line Phase 2a Results for CAT-2054 - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced top-line results from its Phase 2a clinical ...
05/25/16 01:58 PMTarget Check and Stock Performance Recap Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Wall Street Hints and News - Target Check and Stock Performance Recap Catabasis Pharmaceuticals Inc (NASDAQ:CATB)Wall Street Hints and NewsIn recent session activity, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares have traded +12.77%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has ...and more »
05/25/16 01:58 PMEarnings Review and Stock Rundown for Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Wall Street Hints and News - Earnings Review and Stock Rundown for Catabasis Pharmaceuticals Inc (NASDAQ:CATB)Wall Street Hints and NewsEarnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Catabasis Pharmaceuticals Inc (NASDAQ:CATB) to post quarterly EPS of $-0.64. The company is expected to next publish earnings on or ...and more »
05/22/16 01:57 PMCatabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT ... - Business Wire (press release) - Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT ...Business Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced positive pre-clinical data supporting CAT-2054 as a potential treatment for nonalcoholic ...and more »
05/22/16 01:57 PMRevenue Update on Catabasis Pharmaceuticals Inc(NASDAQ:CATB) - Trade Calls - Revenue Update on Catabasis Pharmaceuticals Inc(NASDAQ:CATB)Trade CallsCatabasis Pharmaceuticals Inc(NASDAQ:CATB) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 12, 2016. Earnings per share were $-0.61. Analysts had estimated an EPS of $-0.64. In a different ...Is it Time to Cash in Profits on Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)Franklin Independentall 2 news articles »
05/21/16 11:53 AMCatabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT-2054, a Phase 2 Asset, as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced positive pre-clinical data supporting CAT-2054 ...
05/20/16 12:04 PMCATABASIS PHARMACEUTICALS INC Financials -
05/16/16 07:32 AMCatabasis Pharmaceuticals to Present CAT-2054, a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia, at the National Lipid Association 2016 Scientific Sessions - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present CAT-2054, a potential treatment ...
05/16/16 07:32 AMCatabasis Pharmaceuticals to Present Pre-Clinical Data Supporting CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week 2016 - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that pre-clinical data will be presented that ...
05/13/16 01:06 PMEdited Transcript of CATB earnings conference call or presentation 12-May-16 8:30pm GMT -
05/12/16 04:27 PMCatabasis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Corporate Highlights - [at noodls] - -- Edasalonexent (CAT-1004) as a Potential Treatment for Duchenne Muscular Dystrophy (DMD): MoveDMD Part B (Phase 2) Trial Initiated Following Positive Safety, Tolerability, Pharmacokinetic and NF-kB Biomarker ...
05/12/16 03:12 PMCatabasis Pharmaceuticals posts 1Q loss -

Social

About Catabasis Pharmaceuticls

Catabasis Pharmaceuticls logoCatabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CATB
  • CUSIP:
Key Metrics:
  • Previous Close: $3.62
  • 50 Day Moving Average: $3.84
  • 200 Day Moving Average: $5.06
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $57.65M
  • Current Year EPS Consensus Estimate: $-2.58 EPS
  • Next Year EPS Consensus Estimate: $-2.4 EPS
Additional Links:
Catabasis Pharmaceuticls (NASDAQ:CATB) Chart for Friday, July, 29, 2016